Favorable Outcome in Stage I-II Mantle Cell Lymphoma: A Report of 160 Patients From the International Lymphoma Radiation Oncology Group (ILROG)

Radiation Therapy Is an Effective Modality in the Treatment of Mantle Cell Lymphoma, Even in Heavily Pretreated Patients

“…The International Lymphoma Radiation Oncology Group (ILROG) recently reported the outcomes of 82 patients with stage I-II MCL. 26 The 5-year OS of patients treated with combined chemotherapy and RT was 68%, and the 5-year OS of patients treated with upfront definitive RT alone was 92%, demonstrating that the use of RT leads to favorable disease control and long-term survival. The present study included patients with predominantly advanced MCL, with 87.6% having stage III or IV disease, supporting a role for RT for patients with advanced-stage MCL.…”

Management Trends and Outcomes for Stage I to II Mantle Cell Lymphoma Using the National Cancer Data Base: Ascertaining the Ideal Treatment Paradigm

“…In 2 retrospective studies of 26 patients each, all with stage I-II MCL, the median survival and 5-year OS rates were 6.4 to 6.8 years and 62% to 68% (17,18). The International Lymphoma Radiation Oncology Group presented data from 160 patients with stage I-II MCL and identified a 5-year OS rate of 76% (19). In the present study, the median survival and 5-year OS rates were 6.4 years and 57.4%, respectively, reaffirming comparably favorable outcomes in this group in contrast to historical beliefs.…”

“…Such data suggest that MCL is indeed radiosensitive. Furthermore, patients from the International Lymphoma Radiation Oncology Group database treated with RT alone had favorable outcomes with 5-year diseasefree survival and OS rates of 87% and 88%, respectively (19). The responsiveness to RT might account for the favorable outcomes seen with RT alone or with the addition of RT after CT.…”